How much funding has Novira Therapeutics raised?

Novira Therapeutics has raised $25.0M in total funding, most recently a Series A round.

Who are Novira Therapeutics's investors?

Novira Therapeutics's investors include 5AM Ventures, Canaan Partners, Jerel Davis.

When was Novira Therapeutics founded?

Novira Therapeutics was founded in 2009.

Where is Novira Therapeutics headquartered?

Novira Therapeutics is headquartered in Doylestown, Pennsylvania, United States.

What industry is Novira Therapeutics in?

Novira Therapeutics operates in Antiviral Therapeutics, Biotech.

How many employees does Novira Therapeutics have?

Novira Therapeutics has 1-10 employees.

Novira Therapeutics

Doylestown, United States · Founded 2009 · $25.0M raised

Antiviral Therapeutics

Biotech

Headquarters: Doylestown, Pennsylvania
Employees: 1–10
Founded: 2009
Business Model: B2B

Website: noviratherapeutics.com
Total Funding: $25.0M
Last Round: $25.0M Series AAug 2012
Rounds: 1

About

Novira Therapeutics was a Doylestown, Pennsylvania-based clinical-stage biopharmaceutical company focused on discovering and developing first-in-class antiviral treatments for chronic hepatitis B (HBV) and HIV. The company's lead candidate, NVR 3-778, was a small molecule direct-acting antiviral targeting the HBV core/capsid protein for oral administration. Novira raised $25M in funding and was acquired by Johnson & Johnson (Janssen Pharmaceutical) in December 2015. The company is now part of J&J's Infectious Diseases and Vaccines therapeutic area.

Summary

Novira Therapeutics is an Antiviral Therapeutics company based in Doylestown, United States, founded in 2009. It has raised $25.0M in total across 1 round, most recently a $25.0M Series A round in Aug 2012. Investors include 5AM Ventures, Canaan Partners and Jerel Davis.